Compare DAIO & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAIO | LNAI |
|---|---|---|
| Founded | 1969 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.4M | 23.9M |
| IPO Year | N/A | N/A |
| Metric | DAIO | LNAI |
|---|---|---|
| Price | $3.18 | $1.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.22 | N/A |
| AVG Volume (30 Days) | 26.6K | ★ 3.0M |
| Earning Date | 10-30-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,701,000.00 | N/A |
| Revenue This Year | $9.14 | N/A |
| Revenue Next Year | $2.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.88 | $0.81 |
| 52 Week High | $3.57 | $20.40 |
| Indicator | DAIO | LNAI |
|---|---|---|
| Relative Strength Index (RSI) | 63.46 | N/A |
| Support Level | $2.86 | N/A |
| Resistance Level | $3.20 | N/A |
| Average True Range (ATR) | 0.15 | 0.00 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 94.55 | 0.00 |
Data I/O Corp is a provider of programming, security deployment, security provisioning, and associated Intellectual Property protection and management solutions used in electronics manufacturing with flash memory, microcontrollers, and flash memory-based intelligent devices as well as secure element devices, authentication devices, and secure microcontrollers. It is engaged in focused on the design, manufacturing and sale of programming systems used by designers and manufacturers of electronic products. It has its geographic presence in the United States, Europe, and Asia and others. The company derives the majority of its revenue from Asia and others.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.